Trials / Recruiting
RecruitingNCT06076200
Population Pharmacokinetic of Piperacillin/Tazobactam in Maternal and Neonatal Populations
Population Pharmacokinetic of Piperacillin/Tazobactam in Maternal and Neonatal Populations With High Risk for EOS
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (estimated)
- Sponsor
- Shandong University · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to describe the population pharmacokinetic characteristics of piperacillin/tazobactam after intravenous administration in pregnant women during pregnancy and delivery, and to evaluate pharmacodynamic effectiveness and safety of piperacillin/tazobactam in pregnant women whose baby are at high risk of developing early-onset sepsis after birth.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Piperacillin Sodium and Tazobactam Sodium for Injection | Piperacillin/Tazobactam, specification: 4g; 0.5g. Anti-infective therapy with piperacillin/tazobactam, specific regimen based on clinical practice, without intervention. |
Timeline
- Start date
- 2023-09-30
- Primary completion
- 2026-07-01
- Completion
- 2026-12-31
- First posted
- 2023-10-10
- Last updated
- 2023-10-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06076200. Inclusion in this directory is not an endorsement.